WALTHAM, Mass., Apr 27, 2009 (BUSINESS WIRE) -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving
science, today announced it has entered into an agreement to acquire
Biolab, the leading provider of analytical instruments, life science
consumables and laboratory equipment for scientific, environmental and
healthcare markets in Australia and New Zealand, for AUD $175 million
(approximately USD $120 million). The transaction is expected to be
completed on April 30, 2009. Biolab is the Scientific and Medical
Division of Alesco Corporation Limited (ASX: ALS).
"As the premier commercial channel in Australia, New Zealand and the
South Pacific, Biolab offers a broad portfolio of products and services
to support Thermo Fisher's continued growth in the region," said Marijn
E. Dekkers, president and chief executive officer of Thermo Fisher
Scientific. "This acquisition significantly strengthens our presence in
these markets, and will enable us to better serve customers in both
public and private sectors through an expanded range of offerings."
During its nearly 150-year history, Biolab has become highly regarded
for its market-leading product portfolio, unparalleled service offering,
as well as its customer-focused technical sales capability. It has
annual revenues of approximately AUD $170 million (USD $120 million) and
will be integrated into Thermo Fisher's Laboratory Products and Services
Segment.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science, enabling our customers to make the world healthier, cleaner and
safer. With 2008 revenues of $10.5 billion, we have approximately 34,000
employees and serve over 350,000 customers within pharmaceutical and
biotech companies, hospitals and clinical diagnostic labs, universities,
research institutions and government agencies, as well as environmental
and industrial process control settings. Serving customers through two
premier brands, Thermo Scientific and Fisher Scientific, we help solve
analytical challenges from routine testing to complex research and
discovery. Thermo Scientific offers customers a complete range of
high-end analytical instruments as well as laboratory equipment,
software, services, consumables and reagents to enable integrated
laboratory workflow solutions. Fisher Scientific provides a complete
portfolio of laboratory equipment, chemicals, supplies and services used
in healthcare, scientific research, safety and education. Together, we
offer the most convenient purchasing options to customers and
continuously advance our technologies to accelerate the pace of
scientific discovery, enhance value for customers and fuel growth for
shareholders and employees alike. Visit www.thermofisher.com.
The following constitutes a "Safe Harbor" statement under the Private
Securities Litigation Reform Act of 1995: This press release contains
forward-looking statements that involve a number of risks and
uncertainties. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking
statements are set forth in the Company's Annual Report on Form 10-K for
the year ended December 31, 2008, under the caption "Risk Factors,"
which is on file with the Securities and Exchange Commission and
available in the "Investors" section of our Website under the heading
"SEC Filings." Important factors that could cause actual results to
differ materially from those indicated by forward-looking statements
include risks and uncertainties relating to: competition and its effect
on pricing, spending, third-party relationships and revenues; the
need to develop new products and adapt to significant technological
change; implementation of strategies for improving internal growth; general
worldwide economic conditions and related uncertainties; dependence
on customers' capital spending policies and government funding policies;
the effect of exchange rate fluctuations on international operations;
use and protection of intellectual property; the effect of
changes in governmental regulations; the effect of laws and
regulations governing government contracts; the effect of competing with
certain of our customers and suppliers; and the effect of rapid changes
in the healthcare industry. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so, even if our estimates change and, therefore, you
should not rely on these forward-looking statements as representing our
views as of any date subsequent to today.
SOURCE: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Media Contact Information:
Vaughn Harring, 781-622-1242
vaughn.harring@thermofisher.com
www.thermofisher.com
or
Investor Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
